On October 27, 2023, the calcium gluconate and sodium chloride injection applied by Genchain received the registration approval document issued by NMPA,China. Genchain is the fourth company in the country to obtain approval for this product under generic drug category 3.1. This approval is also the first generic drug approval document obtained of US.

Calcium gluconate and sodium chloride injection is a commonly used calcium supplement in clinical practice. Its main indications are acute hypocalcemia, magnesium poisoning, and fluorosis. According to IMS China pharmaceutical market statistics, the annual sales volume of calcium gluconate injection in China has been stable at more than 1 billion yuan for several years.

Genchain's early product portfolio mainly revolves around the new national drug reform policy. It is expected that nearly 30 of the company's more than 40 projects are expected to catch up with the country's first batch of centralized procurement. Through centralized procurement, Genchain can become one of the main supplier with a large share of my country's medical institutions market in the next five years. In order to achieve sustainable development, the company is currently planning to introduce international elements. On the one hand, it will graft international resources in raw material procurement, research and development and other aspects, enter the field of complex generic drug development, and selectively intervene in the blue ocean track. On the one hand, it explores the licensing introduction path, introduces innovative drugs from Europe and other regions in a timely manner, and uses a differentiated strategy to enhance Genchain's competitiveness in the domestic pharmaceutical market. At the same time, relying on Hainan's location advantages and free trade zone policy support, we are targeting international markets such as Southeast Asia and Europe in product development and design, product clinical layout, production system and quality system construction, market expansion, etc., becoming a globally competitive industry. and brand reputation of pharmaceutical companies.